About Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:TENX
- CUSIP: N/A
- Web: www.tenaxthera.com
- Current Ratio: 10.43%
- Quick Ratio: 4.12%
Sales & Book Value:
- Annual Sales: $40,000.00
- Price / Sales: 289.46
- Book Value: $0.36 per share
- Price / Book: 1.14
- Trailing EPS: ($1.32)
- Net Income: ($43,920,000.00)
- Return on Equity: -89.80%
- Return on Assets: -70.67%
- Employees: 11
- Outstanding Shares: 28,240,000
Frequently Asked Questions for Tenax Therapeutics (NASDAQ:TENX)
What is Tenax Therapeutics' stock symbol?
Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."
How were Tenax Therapeutics' earnings last quarter?
Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings data on Tuesday, December, 15th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. View Tenax Therapeutics' Earnings History.
Where is Tenax Therapeutics' stock going? Where will Tenax Therapeutics' stock price be in 2017?
1 brokers have issued 12-month price objectives for Tenax Therapeutics' shares. Their predictions range from $2.50 to $2.50. On average, they expect Tenax Therapeutics' stock price to reach $2.50 in the next twelve months. View Analyst Ratings for Tenax Therapeutics.
Who are some of Tenax Therapeutics' key competitors?
Some companies that are related to Tenax Therapeutics include Oxford Pharmascience Group Plc (OXP), OncoGenex Pharmaceuticals (ACHV), OpGen (OPGN), Synairgen plc (SNG), Repros Therapeutics (RPRX), Novogen Limited (NVGN), RXi Pharmaceuticals Corporation (RXII), Jaguar Animal Health (JAGX), Ixico Plc (IXI), Senestech (SNES), Metabolix (YTEN), Sorrento Tech (ROKA), Akers Biosciences (AKR), Rosetta Genomics (ROSG), Celator Pharmaceuticals (CPXX), Cyprotex plc (CRX), Durata Therapeutics (DRTX) and GenVec (GNVC).
Who are Tenax Therapeutics' key executives?
Tenax Therapeutics' management team includes the folowing people:
- Ronald R. Blanck, Independent Chairman of the Board (Age 74)
- Michael B. Jebsen CPA, President, Interim Chief Executive Officer, Chief Financial Officer (Age 44)
- Douglas Hay Ph.D., Executive Vice President - Regulatory Affairs
- Doug Randall, Executive Vice President - Business and Commercial Operations
- Paula Bokesch, Chief Medical Officer
- James Mitchum, Director (Age 62)
- Gerald T. Proehl, Director (Age 58)
- Anthony DiTonno, Independent Director (Age 68)
- Gregory Pepin, Independent Director (Age 32)
- Chris A. Rallis, Independent Director (Age 61)
Who owns Tenax Therapeutics stock?
Tenax Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Financial Advisory Service Inc. (4.58%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.
Who bought Tenax Therapeutics stock? Who is buying Tenax Therapeutics stock?
Tenax Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Financial Advisory Service Inc.. Company insiders that have bought Tenax Therapeutics stock in the last two years include Gerald T Proehl and Ronald R Blanck. View Insider Buying and Selling for Tenax Therapeutics.
How do I buy Tenax Therapeutics stock?
Shares of Tenax Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tenax Therapeutics' stock price today?
One share of Tenax Therapeutics stock can currently be purchased for approximately $0.41.
How big of a company is Tenax Therapeutics?
Tenax Therapeutics has a market capitalization of $11.58 million and generates $40,000.00 in revenue each year. The specialty pharmaceutical company earns ($43,920,000.00) in net income (profit) each year or ($1.32) on an earnings per share basis. Tenax Therapeutics employs 11 workers across the globe.
How can I contact Tenax Therapeutics?
Tenax Therapeutics' mailing address is 1 Copley Pkwy Ste 490, MORRISVILLE, NC 27560-9693, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8064414 or via email at [email protected]
MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Tenax Therapeutics (NASDAQ:TENX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$2.50 (509.76% upside)|
Consensus Price Target History for Tenax Therapeutics (NASDAQ:TENX)
Analysts' Ratings History for Tenax Therapeutics (NASDAQ:TENX)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/18/2017||Ladenburg Thalmann Financial Services||Upgrade||Neutral -> Buy||$2.50||High|
Earnings History and Estimates Chart for Tenax Therapeutics (NASDAQ:TENX)
Earnings History by Quarter for Tenax Therapeutics (NASDAQ TENX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Tenax Therapeutics (NASDAQ:TENX)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Tenax Therapeutics (NASDAQ:TENX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tenax Therapeutics (NASDAQ TENX)
Insider Ownership Percentage: 9.81%
Institutional Ownership Percentage: 11.06%
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ TENX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/23/2016||Gerald T Proehl||Director||Buy||29,882||$1.67||$49,902.94|| |
|11/19/2015||Ronald R Blanck||Director||Buy||4,700||$3.26||$15,322.00|| |
|1/20/2015||Ronald R Blanck||Director||Buy||2,000||$3.49||$6,980.00|| |
Headline Trends for Tenax Therapeutics (NASDAQ:TENX)
Latest Headlines for Tenax Therapeutics (NASDAQ TENX)
|How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics|
www.bizjournals.com - August 4 at 8:54 AM
|TENX: FDA Response on Levosimendan|
finance.yahoo.com - August 3 at 7:52 AM
|Tenax Therapeutics Provides Regulatory Update on Levosimendan|
finance.yahoo.com - July 29 at 7:50 AM
|Tenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA Submission|
www.streetinsider.com - May 16 at 8:10 PM
|Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns|
www.streetinsider.com - April 7 at 11:21 PM
|Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.com|
www.streetinsider.com - April 7 at 12:58 PM
|Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update|
www.streetinsider.com - March 22 at 12:57 AM
|BUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - Nasdaq|
www.nasdaq.com - March 21 at 7:54 PM
|Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.com|
www.streetinsider.com - March 21 at 7:54 PM
|Q4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open|
biz.yahoo.com - March 21 at 9:57 AM
|TENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St|
biz.yahoo.com - March 17 at 8:13 PM
|TENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 16 at 9:13 PM
|Tenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT News|
www.rttnews.com - February 3 at 6:11 AM
|Tenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study News|
www.rttnews.com - February 2 at 5:55 AM
|9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)|
us.rd.yahoo.com - February 2 at 5:55 AM
|Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery|
us.rd.yahoo.com - February 2 at 5:55 AM
|Tenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.com|
www.streetinsider.com - February 1 at 6:52 AM
|Tenax Therapeutics: Will It Or Won't It?|
www.rttnews.com - January 30 at 11:29 AM
Tenax Therapeutics (NASDAQ TENX) Chart for Saturday, November, 18, 2017